ClinicalTrials.gg
RecruitingNCT07275606CABNATEUpdated May 19, 2026

A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1

A Phase 1/2 interventional study of Oral CAB and IM CAB LA in HIV Infections, sponsored by ViiV Healthcare. Recruiting at 1 site in South Africa. Open to participants aged Up to 10 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1/2, Interventional, and Prevention

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
44
Allocation
Non-randomized
Ages
Up to 10 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.

Planned enrollment
29th of 36
44 · median 200
Started
2026
with 1 other
Phase 1/2
2 of 36
1 open now
Primary completion
2029-10
later than 11 of 12 live
Registered
36th of 36
by date
Lead sponsor
24 of 36
ViiV Healthcare

Among the 36 studies testing cabotegravir in HIV Infections, this one is the 29th largest by planned enrollment, is one of 2 that started in 2026, is one of 2 in phase 1/2, reaches primary completion later than 11 of the 12 other live ones, and was the 36th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cabotegravir

cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: Up to 10 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cabotegravir in HIV Infections, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of cabotegravir in neonates exposed to human immunodeficiency virus (HIV)-1.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Cabotegravir
  • Neonate
  • HIV
  • Safety
  • Tolerability
  • Pharmacokinetics
04

Who can participate

Ages eligible
Up to 10 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 37 weeks gestation at delivery.
  • \<=10 days of life.
  • Birth weight at least 2 kg.
  • At Entry, neonate has initiated standard of care Antiretroviral drug (ARV) prophylaxis.
  • At Entry, neonate is generally healthy as determined by the site Investigator based on review of all available medical history information and physical examination findings.
  • Mother is on a Dolutegravir (DTG) based regimen for a minimum of 4 weeks prior to delivery, regardless of maternal viral load.
  • Mother is currently breastfeeding or plans to breastfeed infant.
  • Mother is of legal age or circumstance to provide independent and is willing and able to provide documented informed consent for her and her infant's participation in this study.
  • Mother has confirmed -1 infection based on positive test results from 2 samples collected from 2 separate blood samples. Test results may be obtained from medical records or from testing performed during the study Screening period.

Exclusion criteria

Exclusion Criteria:

Medical conditions

  • Severe congenital malformation or other medical condition not compatible with life or that would interfere with study participation or interpretation, as judged by examining clinician.
  • Known maternal-fetal blood group incompatibility which can result in hemolytic disease of the newborn.
  • Known family history of G6PD deficiency.
  • Prior/Concomitant therapy
  • Mother who has previously received, is receiving, or will be receiving CAB post-partum.
  • Neonate or breastfeeding mother is receiving any disallowed medication.
  • Prior/Concurrent clinical study participation
  • Neonate has exposure to other drugs that might interfere with study intervention metabolism.
  • Diagnostic assessments
  • Mother has known Integrase strand transfer inhibitor (InSTI) resistance.
  • At Entry, neonate with a confirmed, documented positive Nucleic acid amplification test (NAAT) test result.
  • At Screening, neonate has any of the following laboratory test results:

    • or Aspartate aminotransferase of more than 2.5 x (ULN).
    • Total in range for phototherapy at Entry.
    • \<13.0 g/dL.
    • Decreased white blood cells Grade 3 or above.
    • \<50 000 cells/mm3
    • Creatinine value more than 1.3 the ULN for postnatal age as defined in Division of AIDS (DAIDS)
    • Albumin Grade 3 or higher.
    • Direct bilirubin Grade 3 and above.
  • Any other Grade ≥3 event on DAIDS toxicity table
  • Neonates with prior exchange transfusion. Other exclusion criteria
  • Mother or neonate has a condition that, in the site Investigator or designee's opinion, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
  • Neonate is receiving DTG as part of HIV prophylactic regimen. Liver safety exclusion criteria
  • Known maternal infection. Cardiac safety exclusion criteria
  • At screening, corrected using Fridericia's formula >450 msec.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Stage 1: Single Oral Dose CAB (Cohort 1) group

    Participants receive a single dose of oral CAB suspension on study Day 1.

    Drug: Oral CAB

  • Experimental
    Stage 1: Multiple Oral Dose CAB (Cohort 2) group

    Participants receive repeat doses of oral CAB suspension starting on study Day 1. Dose and dosing frequency to be determined based on data from Cohort 1.

    Drug: Oral CAB

  • Experimental
    Stage 2: Single IM Dose CAB LA (Cohort 3) group

    Participants receive a single IM dose of CAB LA on study Day 1. Dose to be determined based on data from Cohort 2.

    Drug: IM CAB LA

  • Experimental
    Stage 2: Multiple IM Dose CAB LA (Cohort 4) group

    Participants receive repeat IM doses of CAB LA starting on study Day 1. Dose and dosing frequency to be determined based on data from Cohort 3.

    Drug: IM CAB LA

Interventions

  • CAB administered once orally on study Day 1 to the Stage 1: Single Oral Dose CAB (Cohort 1) and multiple times to the Stage 1: Multiple Oral Dose CAB (Cohort 2) group. Dose and dosing frequency for Cohort 2 to be determined based on emerging data from Cohort 1.

    Also known as: Cabotegravir

  • DrugIM CAB LA

    CAB LA administered once intramuscularly on study Day 1 to the Stage 2: Single IM Dose CAB LA (Cohort 3) group and multiple times to the Stage 2: Multiple IM Dose CAB LA (Cohort 4) group, into the in the anterolateral thigh muscle of participants. Dose for Cohort 3 to be determined based on emerging data from Cohort 2. Dose and dosing frequency for Cohort 4 to be determined based on emerging data from Cohort 3.

    Also known as: Cabotegravir long-acting

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) of CAB in participants from Stage 1: Single Oral Dose CAB (Cohort 1) group

    Blood samples are collected at specific time points for PK analysis to determine Cmax.

    Time frame: At study Days 1, 3, 8, 15 and 22

  2. Maximum observed plasma concentration (Cmax) of CAB LA in participants from Stage 2: Single IM Dose CAB LA (Cohort 3) group

    Blood samples are collected at specific time points for PK analysis to determine Cmax.

    Time frame: At study Days 1, 3, 9,16, 28 and 42

  3. Last observed plasma concentration (Clast) of CAB in participants from Stage 1: Single Oral Dose CAB (Cohort 1) group

    Blood samples are collected at specific time points for PK analysis to determine Clast.

    Time frame: At study Days 1, 3, 8, 15 and 22

  4. Last observed plasma concentration (Clast) of CAB LA in participants from Stage 2: Single IM Dose CAB LA (Cohort 3) group

    Blood samples are collected at specific time points for PK analysis to determine Clast.

    Time frame: At study Days 1, 3, 9, 16, 28 and 42

  5. Area under the curve time 0 to the last time point (AUC0-t) of CAB in participants from Stage 1: Single Oral Dose CAB (Cohort 1) group

    Blood samples are collected at specific time points for PK analysis to determine AUC0-t.

    Time frame: At study Days 1, 3, 8, 15 and 22

  6. Area under the curve time 0 to the last time point (AUC0-t) of CAB LA in participants from Stage 2: Single IM Dose CAB LA (Cohort 3) group

    Blood samples are collected at specific time points for PK analysis to determine AUC0-t.

    Time frame: At study Days 1, 3, 9, 16, 28 and 42

  7. Pre-dose concentrations (C0h) of CAB in participants from Stage 1: Multiple Oral Dose CAB (Cohort 2) group

    Blood samples are collected at specific time points for PK analysis to determine C0h.

    Time frame: At Study Days 1, 3, 7, 14, 28, 35, 42 and 49

  8. Pre-dose concentrations (C0h) of CAB LA in participants from Stage 2: Multiple IM Dose CAB LA (Cohort 4) group

    Blood samples are collected at specific time points for PK analysis to determine C0h.

    Time frame: At Study Days 1, 3, 7, 21, 28, 42, 56, 70, 84, 98, 112, 140 and 168

  9. Post-dose concentrations of CAB in participants from Stage 1: Multiple Oral Dose CAB (Cohort 2) group

    Blood samples are collected at specific time points for PK analysis to determine post-dose concentrations.

    Time frame: At Study Days 1, 3, 7, 14, 21, 28, 35, 42 and 49

  10. Post-dose concentrations of CAB LA in participants from Stage 2: Multiple IM Dose CAB LA (Cohort 4) group

    Blood samples are collected at specific time points for PK analysis to determine post-dose concentrations.

    Time frame: At Study Days 1, 3, 7, 14, 21, 28, 35, 42, 56, 70, 84, 98, 112, 140 and 168

  11. Number of participants with drug-related adverse event (AEs) by severity

    A drug-related AE is any untoward medical occurrence in a clinical study participant considered related to the study intervention. The severity of events is graded using the DAIDS grading scale, where grades are defined based on numeric criteria as follows: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe and Grade 4 = potentially life-threatening. A higher grade indicates greater severity.

    Time frame: From Day 1 up to 2-months post last dose administration (last dose administered at Day 1 to the single dose groups, at Month 1 to Stage 1: Multiple Oral Dose CAB (Cohort 2) group and at Month 6 to Stage 2: Multiple IM Dose CAB LA (Cohort 4) group)

  12. Number of participants with serious AEs (SAEs) by severity

    An SAE is defined as any untoward medical occurrence that is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or results in death. The severity of events is graded using the DAIDS grading scale, where grades are defined based on numeric criteria as follows: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe and Grade 4 = potentially life-threatening. A higher grade indicates greater severity.

    Time frame: From Day 1 up to 2-months post last dose administration (last dose administered at Day 1 to the single dose groups, at Month 1 to Stage 1: Multiple Oral Dose CAB (Cohort 2) group and at Month 6 to Stage 2: Multiple IM Dose CAB LA (Cohort 4) group)

  13. Number of participants with injection site reactions (ISRs) by severity

    An ISR is defined as an adverse event which is localized at the injection site, typically includes pain, tenderness, erythema, redness, induration, swelling, nodules or pruritus, but may also encompass other reactions. The severity of events is graded using the DAIDS grading scale, where grades are defined based on numeric criteria as follows: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe and Grade 4 = potentially life-threatening. A higher grade indicates greater severity.

    Time frame: From Day 1 up to 2-months post last dose administration (last dose administered at Day 1 to the single dose groups, at Month 1 to Stage 1: Multiple Oral Dose CAB (Cohort 2) group and at Month 6 to Stage 2: Multiple IM Dose CAB LA (Cohort 4) group)

  14. Number of participants who discontinue the study intervention due to AEs or injection intolerability

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

    Time frame: From Day 1 up to 2-months post last dose administration (last dose administered at Day 1 to the single dose groups, at Month 1 to Stage 1: Multiple Oral Dose CAB (Cohort 2) group and at Month 6 to Stage 2: Multiple IM Dose CAB LA (Cohort 4) group)

Secondary outcomes

  1. Number of participants developing Grade 3 and higher AEs and SAEs, by severity

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or results in death. The severity of events is graded using the DAIDS grading scale, where grades are defined based on numeric criteria as follows: Grade 3 = severe and Grade 4 = potentially life-threatening. A higher grade indicates greater severity.

    Time frame: From Day 1 up to 2-months post last dose administration (last dose administered at Day 1 to the single dose groups, at Month 1 to Stage 1: Multiple Oral Dose CAB (Cohort 2) group and at Month 6 to Stage 2: Multiple IM Dose CAB LA (Cohort 4) group)

  2. Number of participants with Grade 3 and above bilirubin elevation.

    The severity of events is graded using the DAIDS grading scale, where grades are defined based on numeric criteria as follows: Grade 3 = severe and Grade 4 = potentially life-threatening. A higher grade indicates greater severity.

    Time frame: From Day 1 up to 2-months post last dose administration (last dose administered at Day 1 to the single dose groups, at Month 1 to Stage 1: Multiple Oral Dose CAB (Cohort 2) group and at Month 6 to Stage 2: Multiple IM Dose CAB LA (Cohort 4) group)

07

Study locations

1 of 1 sites recruiting
  • GSK Investigational Site
    Parow Valley, 7505, South Africa
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.viiv-studyregister.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Oct 2029, 41 months after the start.

Of 42 phase 1/2 interventional studies under HIV Infections, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 73. This study's planned 41 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2025
First posted
Dec 10, 2025
StartActual
Apr 15, 2026
Primary completionEst.
Oct 10, 2029
CompletionEst.
Oct 10, 2029
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07275606
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Dec 10, 2025
Start date
Apr 15, 2026
Primary completion
Oct 10, 2029 (estimated)
Completion
Oct 10, 2029 (estimated)
Last update
May 19, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabotegravir

Start the discussion